Stock Scorecard



Stock Summary for Merck & Co Inc (MRK) - $115.51 as of 3/18/2026 7:49:50 PM EST

Total Score

9 out of 30

Safety Score

57 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MRK

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MRK

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MRK

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MRK

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MRK (57 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 6
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for MRK

FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs 3/18/2026 11:37:00 PM
Clinical Progress and Disclosure Timeline: Biopharmaceutical company Pliant Therapeutics (NASDAQ: PLRX) announced that Phase I clinical trial data for its solid tumor candidate drug Pln-101095 will be officially released at the 2026 American Association f 3/18/2026 10:08:00 PM
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs 3/18/2026 8:30:00 PM
Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not the Broader Pipeline 3/18/2026 4:32:00 PM
Elevance Health’s Medicare Crisis and $5 Billion Cash Floor: The Bull Case Explained 3/18/2026 3:37:00 PM
Peripheral T Cell Lymphomas Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma, Citius Pharma, Innate 3/18/2026 2:38:00 PM
Radnet Stock: Here’s Why Numbers Point to 200% Upside Scenario 3/18/2026 1:39:00 PM
Animal Health Market size to reach $199.1 Billion by 2035 | Key 3/18/2026 1:09:00 PM
Synthetic Biology Market to Reach US$ 67.47 Billion by 2033 | Leading Companies 2026 - Illumina, Inc., Merck KGaA, Thermo Fisher Scientific Inc. 3/18/2026 1:09:00 PM
Experimental pill for immunotherapy-resistant tumors set for 2026 AACR data debut 3/18/2026 1:08:00 PM

Financial Details for MRK

Company Overview

Ticker MRK
Company Name Merck & Co Inc
Country N/A
Description Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 12/31/2025
Next Earnings Date 4/30/2026

Stock Price History

Last Day Price 115.51
Price 4 Years Ago 101.27
Last Day Price Updated 3/18/2026 7:49:50 PM EST
Last Day Volume 7,952,157
Average Daily Volume 12,077,353
52-Week High 125.14
52-Week Low 71.26
Last Price to 52 Week Low 62.10%

Valuation Measures

Trailing PE N/A
Industry PE 19.11
Sector PE 63.27
5-Year Average PE 23.37
Free Cash Flow Ratio 19.68
Industry Free Cash Flow Ratio 33.34
Sector Free Cash Flow Ratio 24.55
Current Ratio Most Recent Quarter 1.54
Total Cash Per Share 5.87
Book Value Per Share Most Recent Quarter 21.26
Price to Book Ratio 5.46
Industry Price to Book Ratio 4.04
Sector Price to Book Ratio 25.41
Price to Sales Ratio Twelve Trailing Months 4.41
Industry Price to Sales Ratio Twelve Trailing Months 3.16
Sector Price to Sales Ratio Twelve Trailing Months 5.91
Analyst Buy Ratings 15
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 2,472,392,000
Market Capitalization 285,585,999,920
Institutional Ownership N/A

Dividends

Ex-Dividend Date 3/16/2026
Previous Dividend Amount 0.8500
Current Dividend Amount 0.8500
Total Years Dividend Increasing Dividend Contender - Increasing for 15 Years
Trailing Annual Dividend Rate 3.32
Trailing Annual Dividend Yield 2.86%
Forward Annual Dividend Rate 3.40
Forward Annual Dividend Yield 2.93%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 3.12%
5-Year Average Dividend Yield 3.01%
1-Year Dividend Growth Rate Percentage 3.66%
3-Year Dividend Growth Rate Percentage 1.81%
5-Year Dividend Growth Rate Percentage 4.97%
All-Time Dividend Growth Rate Percentage 9.06%
Dividend Payout Ratio 45.67%

Income Statement

Quarterly Earnings Growth YOY -19.30%
Annual Earnings Growth 6.64%
Reported EPS 12 Trailing Months 7.27
Reported EPS Past Year 8.97
Reported EPS Prior Year 7.64
Net Income Twelve Trailing Months 18,254,000,000
Net Income Past Year 18,254,000,000
Net Income Prior Year 17,117,000,000
Quarterly Revenue Growth YOY 5.00%
5-Year Revenue Growth 9.38%
Operating Margin Twelve Trailing Months 32.80%

Balance Sheet

Total Cash Most Recent Quarter 14,565,000,000
Total Cash Past Year 14,565,000,000
Total Cash Prior Year 13,242,000,000
Net Cash Position Most Recent Quarter -32,185,000,000
Net Cash Position Past Year -32,185,000,000
Long Term Debt Past Year 46,750,000,000
Long Term Debt Prior Year 34,462,000,000
Total Debt Most Recent Quarter 46,750,000,000
Equity to Debt Ratio Past Year 0.53
Equity to Debt Ratio Most Recent Quarter 0.53
Total Stockholder Equity Past Year 52,606,000,000
Total Stockholder Equity Prior Year 46,313,000,000
Total Stockholder Equity Most Recent Quarter 52,606,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 12,360,000,000
Free Cash Flow Per Share Twelve Trailing Months 5.00
Free Cash Flow Past Year 12,360,000,000
Free Cash Flow Prior Year 18,096,000,000

Options

Put/Call Ratio 0.72
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 87.04
20-Day Bollinger Middle Band 107.52
20-Day Bollinger Upper Band 127.99
Beta 0.26
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 3/17/2026 3:32:39 AM EST